|
|
Article: First Phase III Data Positive With BDSI's Buccal Fentanyl.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
Full results come later, but favorable 30-minute results with BioDelivery Sciences International Inc.'s polymer fentanyl disc in a Phase III study for breakthrough cancer pain sent shares rocketing skyward - and brought BDSI another step closer to taking on Cephalon Inc.'s franchise in the space, where patients are still widely untreated, BDSI said.
Shares of Morrisville, N.C.-based BDSI (NASDAQ:BDSI) gained more than 30 percent Wednesday to close at $6.05, up $1.31, after trading as high as $8.26 on word that the firm's BEMA Fentanyl hit the primary efficacy endpoint of the 80-patient trial, Summary of Pain Intensity Difference (SPID) ...